Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViroGates ASOCSE:VIRO 53 Receivables Turnover is 1.40 as of Mar. 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 53/100 and a GF Value™ of kr6.69 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 811 Medical Devices & Instruments companies, ViroGates AS ranks better than 76.08% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ViroGates AS's Revenue for the
three
months ended in Mar. 2026 was kr1.30 Mil. ViroGates AS's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr0.93 Mil.
Hence, ViroGates AS's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.40.
ViroGates AS (OCSE:VIRO) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ViroGates AS Receivables Turnover Related Terms
ViroGates AS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for ViroGates AS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:VIRO vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, ViroGates AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ViroGates AS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS (OCSE:VIRO) has a Receivables Turnover of 1.40 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #194 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 23.9%.
Is ViroGates AS's Receivables Turnover too high?
ViroGates AS's current Receivables Turnover is 1.40. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. ViroGates AS's value of 1.40 is 74.6% below this industry median. Based on the distribution chart, ViroGates AS ranks #194 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ViroGates AS has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #194 out of 811 companies for Receivables Turnover. This places ViroGates AS in the top 24% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.51. ViroGates AS's value of 1.40 is 74.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ViroGates AS's current Receivables Turnover of 1.40 is 74.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current Receivables Turnover is 1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.69, compared to a current price of kr9.55 — trading 42.8% above its estimated fair value. The current Receivables Turnover is 1.40 and 74.6% below the Medical Devices & Instruments industry median of 5.51. ViroGates AS's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Receivables Turnover is 1.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of kr9.55 is trading 42.8% above its estimated GF Value™ of kr6.69.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for OCSE:VIRO:
Receivables Turnover: 1.40
GF Value™: kr6.69 vs. price of kr9.55 (42.8% above fair value)
Industry Position: 74.6% below the Medical Devices & Instruments median (#194 of 811)
No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
53GF Score
Get the complete analysis for OCSE:VIRO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:VIRO has been successfully added to your 
